Evidence map›Paper›PMID 41136752›Full record

ArticleCancer gene therapy2026

Using RNA-seq for detecting MRD in multiple myeloma: high sensitivity and prognostic value.

Yuyue Ren, Ming Liu, Jiancheng Fang, Lianjie Wang, Yanming Xue, Weiwei Zhao, Juan Liu, Liqian Yu, Yinglan Jin, Liyan Chen and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Yuyue Ren *Department of Hematopathology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China.
Ming Liu *Division of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, Heilongjiang Province, China.
Jiancheng Fang *Division of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, Heilongjiang Province, China.
Lianjie WangDepartment of Hematopathology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China.
Yanming XueDepartment of Hematopathology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China.
Weiwei ZhaoDepartment of Hematopathology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China.
Juan LiuDepartment of Hematopathology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China.
Liqian YuDepartment of Hematopathology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China.
Yinglan JinDepartment of Hematopathology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China.
Liyan ChenDepartment of Hematopathology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China.
Yaoyao TianDepartment of Hematopathology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China.
Xinyu GaoDepartment of Hematopathology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China.
Xiaomin ZhangDepartment of Hematopathology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China.
Biqing HanDepartment of Hematopathology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China.
Dandan YaoDepartment of Hematopathology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China.
Yan SongDepartment of Hematopathology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China.
Xi ChenDepartment of Hematopathology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China.
Fang WangDivision of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, Heilongjiang Province, China.
Xiaoli MaDivision of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, Heilongjiang Province, China.
Hongxing LiuDivision of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, Heilongjiang Province, China. starliu@pku.edu.cn.ORCID 0000-0002-0547-5721
Wei WangDepartment of Hematopathology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China. weiwang0_0@163.com.ORCID 0000-0002-2344-1496

Funding

Natural Science Foundation of Heilongjiang Province LH2022H021
6 · The paper itself

Abstract

Multiple myeloma (MM) is a hematological malignancy characterized by the clonal proliferation of plasma cells. Minimal residual disease (MRD) assessment holds prognostic significance in both newly diagnosed and relapsed MM patients throughout the disease course. PCR-based targeted next-generation sequencing (NGS) methods face limitations in MRD monitoring due to somatic hypermutation (SHM) in MM. This study compares RNA-seq with the targeted IGH-CDR3-DNA-NGS method to identify more sensitive and convenient MRD monitoring techniques. We analyzed 125 samples from 35 MM patients and compared with 42 B-ALL patients, using MiXCR software for sequencing data processing. RNA-seq detected clonal immunoglobulin (IG) sequences in all bone marrow (BM) and peripheral blood (PB) initial samples with a sensitivity of 10

Indexed as

Multiple MyelomaNeoplasm, ResidualRNA-SeqAdultAgedFemaleHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedPrognosis

Identifiers

PMID41136752

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.